Navigation Links
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
Date:12/5/2013

NEW YORK, Dec. 5, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIAD Pharmaceuticals, Inc. ("ARIAD" or the "Company") (NASDAQ GS: ARIA) stock between December 12, 2011 and October 8, 2013. The Complaint alleges that throughout the Class Period defendants made false and misleading statements regarding the safety and efficacy of the leukemia drug Iclusig.

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/ariad-pharmaceuticals-aria.

On October 9, 2013, ARIAD announced that its leukemia drug Iclusig causes more side effects than previously reported; the Company also announced it would halt enrollment in its clinical trials and instruct current Iclusig users to lower their dosage. The Company disclosed that serious arterial thrombosis occurred in 11.8% of Iclusig-treated patients, and that 6.2% of the patients had cerebrovascular events. On this news, ARIAD shares declined $11.31 per share to close at $5.83 per share on October 9, 2013.

If you suffered a loss in ARIAD you have until December 9, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ariad-pharmaceuticals-aria

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Upcoming 2013 Investor Conference Presentation
2. Organovo Provides Guidance on Upcoming Retail Investor Conference
3. Ampio Pharmaceuticals to Present at Upcoming Investor Conference
4. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
5. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
6. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting
9. Epizyme, Inc. to Present at Upcoming Conferences in November
10. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
11. Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug Applications - Research Report on Alexion, Pacira, pSivida, Momenta and Impax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... , April 27, 2016 Transparency ... "Skincare Devices Market - Global Industry Analysis, Size, Share, ... the report, the global skincare devices market was valued ... to expand at a CAGR of 10.1% from 2015 ... Browse the full Skincare Devices Market (Treatment Device ...
(Date:4/27/2016)... 2016 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer, will present at the Deutsche Bank 41st ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 ... on the Presentations and Webcasts section of Shire,s Investor website ... will be available on this same website for approximately 90 ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... World Patent Marketing , a vertically ... automotive invention that improves the storage features of a pick up truck. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Over the next five ...
(Date:4/29/2016)... Arizona (PRWEB) , ... April 29, 2016 , ... ... Healing and Spiritual Awakening , announces the addition Onnit brand Alpha BRAIN and ... The addition of Onnit brain and mood optimization products to the store is ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... Philadelphia, PA (PRWEB) , ... April 29, 2016 ... ... Pennsylvania announced that student team BioCellection won the $30,000 Perlman Grand Prize of ... Impact Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Dr. ... cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more ... This offer allows patients to learn more about the options currently available to them ...
Breaking Medicine News(10 mins):